Navigation Links
IK4 develops a portable device for detecting Salmonella in under an hour
Date:1/22/2009

This release is available in Spanish.

IK4 Technological Alliance has designed a low-cost, rapid diagnostic device for detecting the presence of Salmonella spp. and other bacteria in less than one hour, a much shorter time than current systems. Unlike others, this project used clinical samples directly, without prior treatment in a laboratory.

The new diagnostic device is effectively a miniature conventional laboratory inside a chip (Lab on a Chip) (see photograph). Moreover, it is highly specific, rapid, portable and user-friendly. In this way, an ample range of possible users -hospitals, health centres and the food industry, amongst others have available a device equipped with an optical reading system (fluorescence signal emitted during Polymerase Chain Reaction (PCR) reaction in real time), that enables the rapid identification of pathogens. Within the Chip the system integrates the concentrating of the sample, the rupture of its membrane, the enzymatic multiplication of its DNA and finally identification of the pathogen. The user only has to insert two syringes into the device and the analysis is undertaken automatically.

This research is within the remit of the European OPTOLABCARD project, launched in September 2005 and now about to finish. The project is led by IKERLAN-IK4 and financed by the VI Framework Programme, with an overall budget of 2.9 million euros, and involving the participation of a total of 9 different bodies DTU-Nano, the Hospital de Donosti through the BIOEF Foundation and GAIKER-IK4 itself, amongst them and from 6 different countries (Germany, Austria, Denmark, Spain, Poland and Sweden).

GAIKER-IK4's participation in the project has focused on the adaptation of biochemical developments to the microfluid system of the chip, as well as the optimisation and characterisation of the device for its clinical application and its diagnosis for the presence of Salmonella spp. in persons with colitis.IKERLAN-IK4 has also worked on the development of manufacturing technology for the production of the Laboratory on a Chip. This advance will enable the development of a great variety of new devices in the future.

The OPTOLABCARD project is currently in its final stage, having developed and patented exclusive technology for Micromanufacture and Molecular Diagnosis. The convergence of these two technologies together with the biological results mentioned corroborate the healthy position of IK4 Technological Alliance and is a great opportunity for the development of various and future laboratories miniaturised on a Chip.

Applications of the new device

Although there are many possible applications for the new device, research in this project has focused on two applications differentiated by the type of samples and the pathogen for detection: the detection of campylobacteriosis in farm animals (animal health application) and the identification of salmonellosis amongst persons (human health application). The final stage of the project involved the validation of the device for these types of samples.

One of the great advantages of this device is the rapidity of the whole process of analysis, including the concentrating and preparation of the sample and the detection of pathogens by PCR, in comparison to the procedures habitually employed in laboratories of reference. Likewise, the device's easy-to-use handling and portability will enable a diagnostic analysis in the doctor's surgery itself.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Couples more likely to divorce if spouse develops cervical or testicular cancer
2. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
3. UCLA doctor develops new technique to treat varicose veins
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. Silverchair Learning Systems Updates and Develops New Courses
6. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
7. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
8. MIT develops thin-film micro pharmacy
9. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
10. Psychologist develops post-operative care for heart patients in Bermuda
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 24, 2017 , ... BayMark Health Services has been awarded ... (SAMHSA) State Targeted Response to the Opioid Crisis program. The funding, awarded ... development of a hub and spoke model for opioid treatment in California. The ...
(Date:7/24/2017)... ... July 24, 2017 , ... Every year, thousands of dedicated Higher Education and ... annual event is coupled with a dynamic theme like Camp Canvas; this year, they’ve ... InstructureCon 0017. , To extend their partnership with Canvas beyond the LMS integration, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global leader in ... of United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent ... and '324 patents cover methods and systems for optimizing fat grafts for current ...
(Date:7/24/2017)... ... 2017 , ... Paul Vitenas, MD, FACS is excited to report that he ... attend Allergan’s recent meeting with their Plastics Advisory Board. As one of the top ... bringing a newly defined structure to the aesthetics market. Dr. Vitenas , along ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, ... Friday, July 28. , Increased FDA scrutiny and growing demands to track and ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... , July 10, 2017  BDI Group ... and patient support services organization serving specialty pharmacies, ... the launch of four significant, value-added member programs ... insights, better manage reimbursement and improve access and ... factor therapies. ...
(Date:7/6/2017)... ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, is celebrating a ... To celebrate its anniversary, ThriveRx recently launched a redesigned website ... with improved organization to create the best user experience for consumers and ... ... "We,ve made several great strides throughout the ...
Breaking Medicine Technology: